June 30, 2020 / 12:41 PM / 10 days ago

BRIEF-Vertex Announces Expansion Of Reimbursement Agreement With NHS England To Include Kaftrio® In Combination With Kalydeco®

June 30 (Reuters) - Vertex Pharmaceuticals Inc:

* VERTEX ANNOUNCES EXPANSION OF REIMBURSEMENT AGREEMENT WITH NHS ENGLAND TO INCLUDE KAFTRIO® (IVACAFTOR/TEZACAFTOR/ELEXACAFTOR) IN COMBINATION WITH KALYDECO® (IVACAFTOR)

* VERTEX PHARMACEUTICALS INC - HAS EXPANDED ITS REIMBURSEMENT AGREEMENT WITH NHS ENGLAND FOR VERTEX’S CYSTIC FIBROSIS MEDICINES

* VERTEX PHARMACEUTICALS - NEW AGREEMENT INCLUDES REIMBURSED ACCESS TO VERTEX’S CURRENTLY LICENSED MEDICINES - KALYDECO, ORKAMBI AND SYMKEVI Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below